Corcept Therapeutics (CORT) Other Non-Current Liabilities (2018 - 2026)

Corcept Therapeutics has disclosed Other Non-Current Liabilities across 9 years of filings, most recently posting $15.3 million for Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $15.3 million, up 7.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.3 million (up 7.57% YoY), and the FY2025 annual result was $15.2 million, up 7.75% from the prior year.
• Other Non-Current Liabilities came in at $15.3 million for Q1 2026 at Corcept Therapeutics, up from $15.2 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $15.7 million in Q2 2025 to a low of $2.5 million in Q1 2022.
• The 5-year median for Other Non-Current Liabilities is $10.9 million (2024), against an average of $11.1 million.
• Across the five-year window, Other Non-Current Liabilities surged 2124.21% in 2022 and grew 7.57% in 2026, its largest moves.
• Corcept Therapeutics' Other Non-Current Liabilities stood at $9.1 million in 2022, then grew by 13.3% to $10.3 million in 2023, then surged by 36.64% to $14.1 million in 2024, then gained by 7.75% to $15.2 million in 2025, then gained by 1.03% to $15.3 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $15.3 million (Q1 2026), $15.2 million (Q4 2025), and $14.1 million (Q3 2025), per Business Quant data.